Physician profile
David Taragin
NPI 1730151986
$22,758.40
in general payments reported to CMS, 2019-2025
72 companies · $2,812 in 2025
The $2,812 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $2,678 · 2021: $3,766 · 2022: $3,882 · 2023: $3,660 · 2024: $3,596 · 2025: $2,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,918 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,918.19 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,941.17 | 2019-2025 | |
| Biogen, INC. | $1,458.73 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Lundbeck LLC | $1,420.85 | 2019-2025 | Vyepti, Rexulti |
| Abbvie INC. | $1,337.45 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Banner Life Sciences, LLC | $1,213.97 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $1,049.18 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Lilly USA, LLC | $1,009.79 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Ucb, INC. | $975.09 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Allergan, INC. | $873.54 | 2019-2021 | |
| Emd Serono, INC. | $811.06 | 2019-2025 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $718.61 | 2019-2022 | |
| Pfizer INC. | $710.02 | 2023-2025 | |
| Genentech USA, INC. | $664.58 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $576.78 | 2019-2025 | Nuplazid |
| Celgene Corporation | $573.52 | 2021-2025 | Zeposia |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Taragin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.